Select Publications
Aapro M et al. Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann Oncol 2011;22(2):257-67. Abstract
Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9. Abstract
Baselga J et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19. Abstract
Baselga J et al. A Phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA). San Antonio Breast Cancer Symposium 2011;Abstract S5-5.
Blackwell K et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Proc ASCO 2012;Abstract LBA1.
Cortés J et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 2011;377(9769):914-23. Abstract
Fabi A et al. HER2 protein and gene variation between primary and metastatic breast cancer: Significance and impact on patient care. Clin Cancer Res 2011;17(7):2055-64. Abstract
Gradishar WJ et al. A randomized Phase II trial of first-line metastatic breast cancer (MBC) patients: Sub-set analysis of albumin-bound paclitaxel (ab-pac) given weekly at 150 mg/m2. San Antonio Breast Cancer Symposium 2011;Abstract P5-19-13.
Gradishar WJ et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27(22):3611-9. Abstract
Perez EA et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25(23):3407-14. Abstract
Punam R, Srikala S. Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) 2012;6:67–77. Abstract
Rugo H et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Proc ASCO 2012;Abstract CRA1002.
Sharon H et al. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24(21):e42-e43. Abstract
Wong AL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012;2012:415170. Abstract